Insmed (INSM) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Insmed Revenue Highlights


Latest Revenue (Y)

$305.21M

Latest Revenue (Q)

$90.34M

Main Geography (Y)

UNITED STATES

Insmed Revenue by Period


Insmed Revenue by Year

DateRevenueChange
2023-12-31$305.21M24.39%
2022-12-31$245.36M30.19%
2021-12-31$188.46M14.63%
2020-12-31$164.41M20.48%
2019-12-31$136.47M1287.56%
2018-12-31$9.84M100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31--100.00%
2014-12-31$11.50M-
2013-12-31$11.50M100.00%
2012-12-31--100.00%
2011-12-31$4.42M-36.18%
2010-12-31$6.92M-33.28%
2009-12-31$10.37M-11.33%
2008-12-31$11.70M55.39%
2007-12-31$7.53M659.74%
2006-12-31$991.00K656.49%
2005-12-31$131.00K-4.38%
2004-12-31$137.00K-8.67%
2003-12-31$150.00K-92.33%
2002-12-31$1.96M560.47%
2001-12-31$296.00K393.33%
2000-12-31$60.00K-90.95%
1999-12-31$663.16K-

Insmed generated $305.21M in revenue during NA 2023, up 24.39% compared to the previous quarter, and up 3103.28% compared to the same period a year ago.

Insmed Revenue by Quarter

DateRevenueChange
2024-06-30$90.34M19.66%
2024-03-31$75.50M-9.79%
2023-12-31$83.69M5.84%
2023-09-30$79.07M2.39%
2023-06-30$77.23M18.42%
2023-03-31$65.21M9.97%
2022-12-31$59.30M-12.45%
2022-09-30$67.73M3.85%
2022-06-30$65.22M22.81%
2022-03-31$53.11M-5.38%
2021-12-31$56.12M20.03%
2021-09-30$46.76M3.07%
2021-06-30$45.37M12.81%
2021-03-31$40.21M-2.90%
2020-12-31$41.41M-5.11%
2020-09-30$43.64M2.70%
2020-06-30$42.49M15.29%
2020-03-31$36.86M-19.36%
2019-12-31$45.71M17.55%
2019-09-30$38.88M29.74%
2019-06-30$29.97M36.85%
2019-03-31$21.90M122.69%
2018-12-31$9.84M100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2017-03-31-100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30--100.00%
2013-06-30$11.50M100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31--100.00%
2011-12-31$1.40M222.53%
2011-09-30$435.00K-55.52%
2011-06-30$978.00K-38.91%
2011-03-31$1.60M21.20%
2010-12-31$1.32M-26.90%
2010-09-30$1.81M-3.06%
2010-06-30$1.86M-3.37%
2010-03-31$1.93M-22.47%
2009-12-31$2.49M0.53%
2009-09-30$2.48M-18.59%
2009-06-30$3.04M28.27%
2009-03-31$2.37M-17.10%
2008-12-31$2.86M-29.77%
2008-09-30$4.07M53.74%
2008-06-30$2.65M14.29%
2008-03-31$2.32M8.17%
2007-12-31$2.14M-

Insmed generated $90.34M in revenue during Q2 2024, up 19.66% compared to the previous quarter, and up 138.53% compared to the same period a year ago.

Insmed Revenue Breakdown


Insmed Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21
UNITED STATES$224.19M$185.99M$159.51M
Europe And The Rest Of The World$15.28M$2.86M$12.95M
JAPAN$65.73M$56.51M$16.01M

Insmed's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (73.46%), JAPAN (21.54%), and Europe And The Rest Of The World (5.01%).

Quarterly Revenue by Country

CountryMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22
UNITED STATES$56.35M$58.26M$59.20M$57.66M$49.07M$48.48M$49.54M$47.19M$3.53M
Europe And The Rest Of The World$4.26M$4.48M$3.84M$3.97M$2.99M$-4.68M$3.71M$2.18M$-1.31M
JAPAN$14.89M$20.95M$16.03M$15.59M$13.16M$15.50M$14.48M$15.85M$10.68M

Insmed's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (74.63%), JAPAN (19.72%), and Europe And The Rest Of The World (5.64%).

Insmed Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BGNEBeiGene$2.46B$929.17M
HALOHalozyme Therapeutics$829.25M$231.35M
HRMYHarmony Biosciences$582.02M$172.81M
RAREUltragenyx Pharmaceutical$434.25M$147.03M
APLSApellis Pharmaceuticals$366.28M$179.14M
INSMInsmed$305.21M$90.34M
ASNDAscendis Pharma$266.72M$95.89M
BPMCBlueprint Medicines$249.38M$138.16M
AGIOAgios Pharmaceuticals$26.82M$8.62M
FENCFennec Pharmaceuticals$21.64M$25.26M
RVMDRevolution Medicines, Inc. Warrant$11.58M-
RNAAvidity Biosciences$9.56M$2.04M
JANXJanux Therapeutics$8.08M$1.25M
SWTXSpringWorks Therapeutics$5.45M$21.01M
KROSKeros Therapeutics$151.00K$83.00K
DAWNDay One Biopharmaceuticals-$8.19M
CERECerevel Therapeutics--
AKROAkero Therapeutics--
EWTXEdgewise Therapeutics--

INSM Revenue FAQ


Insmed's yearly revenue for 2023 was $305.21M, representing an increase of 24.39% compared to 2022. The company's yearly revenue for 2022 was $245.36M, representing an increase of 30.19% compared to 2021. INSM's yearly revenue for 2021 was $188.46M, representing an increase of 14.63% compared to 2020.

Insmed's quarterly revenue for Q2 2024 was $90.34M, a 19.66% increase from the previous quarter (Q1 2024), and a 16.98% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $75.5M, a -9.79% decrease from the previous quarter (Q4 2023), and a 15.77% increase year-over-year (Q1 2023). INSM's quarterly revenue for Q4 2023 was $83.69M, a 5.84% increase from the previous quarter (Q3 2023), and a 41.13% increase year-over-year (Q4 2022).

Insmed's revenue growth rate for the last 3 years (2021-2023) was 61.95%, and for the last 5 years (2019-2023) was 123.65%.